BeOne Medicines Ltd
244 hedge funds and large institutions have $8.34B invested in BeOne Medicines Ltd in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 91 increasing their positions, 83 reducing their positions, and 50 closing their positions.
28.12% more ownership
Funds ownership: 3.32% → 31.44% (+28%)
11% more call options, than puts
Call options by funds: $36.7M | Put options by funds: $33.2M
10% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 83
9% less funds holding
Funds holding: 267 → 244 (-23)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
28% less capital invested
Capital invested by funds: $11.6B → $8.34B (-$3.24B)
44% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$28.5M |
| 2 |
Man Group
London,
United Kingdom
|
+$22.1M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$17.7M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$16.7M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$988M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$415M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$109M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$78M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.8M |
ONC Hedge Fund Activity: Q2 2025 in Review
244 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2025, worth a combined $8.34B — down 28% from $11.6B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of ONC and 28 opened new positions — a net loss of 22 holders — while 83 trimmed existing stakes and 91 added.
The largest buyer was UBS Group, adding an estimated $28.5M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $988M sold.
- 244 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2025, down from 267 in Q1 2025.
- Funds reported $8.34B of BeOne Medicines Ltd stock for Q2 2025, down 28% quarter-over-quarter.
- 28 funds opened new BeOne Medicines Ltd positions in Q2 2025 and 50 closed out, a net change of -22 holders.
- The largest BeOne Medicines Ltd buyer in Q2 2025 was UBS Group, an estimated $28.5M added.
- The largest BeOne Medicines Ltd seller in Q2 2025 was Baillie Gifford & Co, an estimated $988M sold.
Based on aggregated 13F filings for Q2 2025.